Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + bevacizumab + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Atezolizumab + bevacizumab + platinum-based chemotherapy is a combination regimen used primarily for the treatment of advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), and has been studied in ovarian cancer. Atezolizumab is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80, thereby enhancing anti-tumor immune responses. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. Platinum-based chemotherapies, such as carboplatin or cisplatin, are DNA-damaging agents that induce apoptosis in rapidly dividing cells. This combination leverages immunotherapy, antiangiogenic therapy, and cytotoxic chemotherapy to improve survival outcomes in several cancers[1][4][5].
- Other names
- atezo-bev (colloquial abbreviation)bev-atezo (colloquial abbreviation)
02
Targets
Beyond the preview
Go deeper on atezolizumab + bevacizumab + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + bevacizumab + platinum-based chemotherapy.